United States v. Antikamnia Chemical Co.
Headline: Court upholds federal rule requiring drug labels to name the parent substance of chemical derivatives, reversing lower courts and allowing seizure of misbranded Antikamnia tablets while strengthening labeling enforcement.
Holding: The Court reversed lower courts, holding that the Food and Drugs Act and a valid federal regulation require labels to identify chemical derivatives and name their parent substance, permitting condemnation proceedings for misbranded drugs.
- Requires drug labels to state when an ingredient is a derivative and name its parent substance.
- Enables federal seizures and condemnation of mislabeled drug packages.
- Affirms federal agencies’ power to make labeling rules to protect consumers.
Summary
Background
The Government seized about one hundred packages of Antikamnia tablets from a drug wholesaler, alleging the tablets contained acetphenetidin and were misbranded because the labels did not say that acetphenetidin is a derivative of acetanilid and even stated no acetanilid was present. The Antikamnia Chemical Company, the manufacturer, intervened, argued the statute did not require naming the parent substance of a derivative, and the lower courts sustained the company and dismissed the Government’s libel for condemnation. The record included a Department of Agriculture decision and an amended Regulation 28 requiring labels of derivatives to name their parent substance.
Reasoning
The Court asked whether the Food and Drugs Act and lawful regulations can require that a derivative be labeled with the name of the substance from which it is derived. It held the Act’s purpose is to protect purity and inform buyers, that the three Secretaries were given rulemaking power to carry that out, and that requiring the parent name on labels reasonably furthers the law’s warning and information goals. The Court concluded the regulation was a permissible aid to make the statute effective, reversed the decree that dismissed the libel, and sent the case back with directions to overrule the company’s exceptions so condemnation proceedings could continue.
Real world impact
Manufacturers and sellers must disclose on labels when a listed ingredient is a derivative and also name the primary substance, or risk seizure as misbranded. The ruling validates the federal regulation-making process for enforcing labeling rules and strengthens federal enforcement of the 1906 Food and Drugs Act.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?